IDH2 and acute myeloid leukemia: Mutations in IDH1/IDH2, CEBPA, PTPN11, FLT3, and RUNX1 were not limited to any AML-MRC subgroup and could be more significant as risk factors or susceptible markers for target therapy in not only AML-MRC, but also other AML categories.